139 related articles for article (PubMed ID: 23469018)
21. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
22. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
23. SOCS-6 negatively regulates T cell activation through targeting p56lck to proteasomal degradation.
Choi YB; Son M; Park M; Shin J; Yun Y
J Biol Chem; 2010 Mar; 285(10):7271-80. PubMed ID: 20007709
[TBL] [Abstract][Full Text] [Related]
24. The SOCS box-adapting proteins for ubiquitination and proteasomal degradation.
Linossi EM; Nicholson SE
IUBMB Life; 2012 Apr; 64(4):316-23. PubMed ID: 22362562
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.
Hirai M; Kadowaki N; Kitawaki T; Fujita H; Takaori-Kondo A; Fukui R; Miyake K; Maeda T; Kamihira S; Miyachi Y; Uchiyama T
Blood; 2011 Jan; 117(2):500-9. PubMed ID: 20956804
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Ma XZ; Bartczak A; Zhang J; Khattar R; Chen L; Liu MF; Edwards A; Levy G; McGilvray ID
J Virol; 2010 Dec; 84(23):12419-28. PubMed ID: 20861244
[TBL] [Abstract][Full Text] [Related]
27. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
28. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
Mimnaugh EG; Xu W; Vos M; Yuan X; Neckers L
Mol Cancer Res; 2006 Sep; 4(9):667-81. PubMed ID: 16966435
[TBL] [Abstract][Full Text] [Related]
29. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
30. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
31. Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells.
Hong B; Ren W; Song XT; Evel-Kabler K; Chen SY; Huang XF
Cancer Res; 2009 Oct; 69(20):8076-84. PubMed ID: 19789342
[TBL] [Abstract][Full Text] [Related]
32. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Bazzaro M; Lin Z; Santillan A; Lee MK; Wang MC; Chan KC; Bristow RE; Mazitschek R; Bradner J; Roden RB
Clin Cancer Res; 2008 Nov; 14(22):7340-7. PubMed ID: 19010849
[TBL] [Abstract][Full Text] [Related]
33. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Rushworth SA; Bowles KM; MacEwan DJ
Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
[TBL] [Abstract][Full Text] [Related]
34. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling.
van de Geijn GJ; Gits J; Touw IP
J Leukoc Biol; 2004 Jul; 76(1):237-44. PubMed ID: 15107455
[TBL] [Abstract][Full Text] [Related]
35. Increased cytoplasmic levels of CIS, SOCS1, SOCS2, or SOCS3 are required for nuclear translocation.
Lee KH; Moon KJ; Kim HS; Yoo BC; Park S; Lee H; Kwon S; Lee ES; Yoon S
FEBS Lett; 2008 Jun; 582(15):2319-24. PubMed ID: 18538139
[TBL] [Abstract][Full Text] [Related]
36. Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Sha Z; Goldberg AL
Curr Biol; 2014 Jul; 24(14):1573-1583. PubMed ID: 24998528
[TBL] [Abstract][Full Text] [Related]
37. Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins.
Dalpke A; Heeg K; Bartz H; Baetz A
Immunobiology; 2008; 213(3-4):225-35. PubMed ID: 18406369
[TBL] [Abstract][Full Text] [Related]
38. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
Yu HC; Hou DR; Liu CY; Lin CS; Shiau CW; Cheng AL; Chen KF
PLoS One; 2013; 8(2):e55705. PubMed ID: 23383345
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
[TBL] [Abstract][Full Text] [Related]
40. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
